Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Tidewave Bio appoints Prof. Alexander Eggermont as Head of Clinical Advisory Board to advance its biopsy-native immunotherapy for solid tumors.
-
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives...
-
Regeneron is renewing it's sponsorship of the Science Talent Search for the next 10 years, committing $150 million.
-
Nantes, le 26 février 2026 – 18h00 CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) annonce aujourd’hui que le Comité Indépendant de Surveillance des Données (IDMC) a émis une...
-
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
-
Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs....
-
Austin, TX, USA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Laboratory Informatics Market Size, Trends and Insights By Product (Laboratory...
-
MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.
-
kneat.com reports record fourth-quarter and full year 2025 results with highest-ever new customer wins in 2025.
-
GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure-lowering benefits of triple combination therapy early in the treatment pathway, supported by an...